Tempus AI's growth and partnerships make it an attractive investment. See why TEM stock is a solid Buy due to its ...

Piper Sandler analyst David Westenberg raised the firm’s price target on Tempus AI (TEM) to $70 from $40 and keeps a Neutral rating on ...

Stifel has downgraded Tempus AI (NASDAQ:TEM) to hold from buy, citing valuation and uncertainty about core growth in 2025.

Stifel Nicolaus analyst Daniel Arias downgraded the rating on Tempus AI, Inc. Class A (TEM – Research Report) to a Hold yesterday, ...

Fintel reports that on November 11, 2024, Stifel downgraded their outlook for Tempus AI (NasdaqGS:TEM) from Buy to Hold. ...

Aliso Viejo-based Ambry Genetics Corp. on Nov. 4 announced an agreement to be acquired for $600 million by Tempus AI Inc.

CEO Eric Lefkofsky said the purchase of Ambry Genetics will expand Tempus’ testing portfolio and bring in a fast-growing ...

With Ambry Genetics in tow, Eric Lefkofsky's biotech startup hopes to accelerate its drive toward turning a profit.

In addition, please check the fund’s top five holdings to know its best picks in 2024. Baron Discovery Fund highlighted ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, " Actionable structural variant ...

On Friday, Tempus AI Inc (TEM) stock saw a modest uptick, ending the day at $73.77 which represents a slight increase of $16.98 or 29.90% from the prior close of $56.79. The stock opened at $56.79 and ...

Northwestern Medicine will be the first system to use Tempus' new algorithm to identify patients at risk for developing ...